12 results about "Wasting" patented technology

The invention discloses an anti-muscle attenuation composition and application thereof, and the composition provided by the invention comprises an anti-muscle attenuation peptide, WPC, MLCT and CaHMB; the muscle attenuation resisting peptide is zymolyte obtained after milk protein is subjected to protease enzymolysis, the zymolyte comprises polypeptide with the absolute net charge density ridge-shaped region distribution of a peptide chain formed by a head peptide fragment, a middle peptide fragment and a tail peptide fragment, the head peptide fragment is j1, the middle peptide fragment is j2, and the tail peptide fragment is j3; the charge density of the j1 and the charge density of the j3 are both larger than the charge density of the j2, or the charge density of the j1 and the charge density of the j3 are both smaller than the charge density of the j2. Through mutual cooperation of the muscle attenuation resisting peptide, the WPC, the MLCT and the CaHMB, the effect of obviously improving the muscle attenuation resisting effect is achieved.

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

The invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low- molecular-weight polyphenols derived from lychee fruit and green tea leaves. Further, the invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low-molecular-weight polyphenols derived from lychee fruit and green tea leaves for use as a medicament, more particularly for therapeutic use in treating and / or preventing muscle wasting.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The invention discloses lactoprotein hydrolysate with peptide chain absolute net charge density ridge-shaped region distribution and application in muscle attenuation resistance activity, the lactoprotein hydrolysate comprises polypeptide with peptide chain absolute net charge density ridge-shaped region distribution formed by head, middle and tail peptide fragments, the head peptide fragment is j1, the middle peptide fragment is j2, the tail peptide fragment is j3, the middle peptide fragment is j1, and the tail peptide fragment is j2. The charge density of the j1 ranges from-0.0241 e <-1 > / 3 to-0.1224 e <-1 > / 3, the charge density of the j2 ranges from-0.0083 e <-1 > / 3 to-0.1238 e <-1 > / 3, the charge density of the j3 ranges from-0.0472 e <-1 > / 3 to-0.1752 e <-1 > / 3, the charge density of the j1 and the charge density of the j3 are both larger than the charge density of the j2, or the charge density of the j1 and the charge density of the j3 are both smaller than the charge density of the j2. The lactoprotein zymolyte provided by the invention is suitable for preparing products with muscle quality and functional decline characteristics such as prevention or delay of muscle attenuation and the like.

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the amino acid L-Alanine and their use in the prevention and / or treatment of muscle wasting associated to pathological or age-related conditions.

The invention pertains to a nutritional composition comprising xanthohumol, fucoxanthin and c- phycocyanin. Further, the invention pertains to a nutritional composition comprising xanthohumol, fucoxanthin and c-phycocyanin for use as a medicament, more particularly for therapeutic use in treating and / or preventing muscle wasting.

Activin receptor type II (ActRII) - binding proteins, and compositions and methods for making ActRII-binding proteins are provided.SOLUTION: To provide isolated ActRII-binding proteins having specific sequences and binding to activin receptor type IIB (ActRIIB) or ActRIIB and activin receptor type IIA (ActRIIA). In certain aspects, the ActRII-binding protein inhibits or antagonizes ActRII activity. In addition, the disclosure provides compositions and methods of diagnosing and treating diseases and conditions associated with muscle wasting; fibrotic conditions; inflammatory, cardiovascular, pulmonary, musculoskeletal, neurological, ocular, skeletal, autoimmune, or metabolic diseases or conditions; wound healing; and cancer, and other ActRII-mediated diseases and conditions.SELECTED DRAWING: Figure 6

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Use of a ketone body and a ketone body ester for preserving glycogen and / or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of D-β-hydroxybutyrate with R-1,3-butanediol or with glycerol to reduce muscle breakdown and aid muscle recovery after exercise or retard muscle wasting. Compositions containing the ketone bodies or ketone body esters are also described.

The present disclosure relates generally to methods and compositions comprising trigonelline for treating or preventing diseases or conditions associated with muscle decline and / or renal dysfunction. In addition, the invention relates to methods and compositions comprising trigonelline for slowing the progression of glomerular filtration rate (GFR) and / or reducing glomerular vitreous lesion injury and / or increasing lean body mass of the muscle. In addition, methods and compositions comprising trigonelline are disclosed for increasing lean body mass of the muscle and / or increasing muscle fiber size. Also disclosed are methods for increasing the level of at least one nicotinamide adenine dinucleotide and compositions comprising trigonelline. Methods and compositions comprising trigonelline for increasing muscle stem cells and / or reducing muscle stem cell decline are also disclosed.